Vedolizumab for the treatment of moderately to severely active Ulcerative colitis
-
-
[1] Hospital Universitario de Puerto Real
Hospital Universitario de Puerto Real
Puerto Real, España
-
- Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 21, Nº. 2, 2019, págs. 96-100
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Ulcerative colitis (UC) is a chronic disease that results in inflammation of gastrointestinal tract. Pivotal GEMINI I clinical trial compares VDZ versus placebo in refractory patients to one or more previous conventional therapies for UC or previous use of anti-TNF. This is a phase III, multicenter, prospective, randomized and double-blind, designed in two phases: induction and maintenance. According to clinical trials, most frequent adverse effects (AE) were headaches, nasopharyngitis, upper respiratory tract infection, arthralgia, nausea, abdominal pain and fatigue. GEMINI I trial studied safety in 895 patients (620 patients with VDZ and 275 with placebo), taking into account non-responders in week 6. Incidence of AE was similar between VDZ and placebo (80% of population in each group), as well as incidence of severe AE (12-13%). VDZ is considered as an effective alternative, in second or third line of treatment of moderate-severe active UC.
